Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9663811 | 0.88 | MAPT (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL743669 | 0.86 | MAPT (0.43) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3597535 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL4469886 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3601328 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3602229 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3592730 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3600856 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3584638 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E | |
| SCHEMBL3587145 | 0.84 | CA12 (0.44) | TRIM24TRIM33CA2CA12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5801183-A | HETEROCYCLC ALCOHOLS FOR NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-09-01 | — | — | US | claimed |
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| EP-1537913-B1 | PALLADIUM CATALYST COMPOSITION | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7183296-B2 | Anti-HIV pyrazole derivatives | ROCHE PALO ALTO LLC (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1341766-B1 | IMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5801183-A | HETEROCYCLC ALCOHOLS FOR NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0805809-A2 | AZA AND AZA (N-OXY) ANALOGS OF GLYCINE/NMDA RECEPTOR ANTAGONISTS | State of Oregon through Oregon State Board of Higher Education for and on behalf of Oregon Health Sc. Univ. & Univ. of Oregon (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022990-A2 | AZA AND AZA (N-OXY) ANALOGS OF GLYCINE/NMDA RECEPTOR ANTAGONISTS | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON (US) | 1996-08-01 | — | — | WO | disclosed |
| US-5475008-A | Selective non-competitive antagonists of n-methyl-d-aspartate receptors | MERCK SHARP & DOHME LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| EP-0459561-B1 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME (GB) | 1995-09-20 | — | — | EP | disclosed |
| EP-0614363-A1 | QUINOLONE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-09-14 | — | — | EP | disclosed |
| US-5268378-A | Oxo group in 2 and 4 position | MERCK SHARP & DOHME, LIMITED (GB) | 1993-12-07 | — | — | US | disclosed |
| WO-1993010783-A2 | QUINOLONE DERIVATIVES AND THEIR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-10 | — | — | WO | disclosed |
| EP-0459561-A2 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | TRIM24 2827/4885TRIM33 3474/4885CA2 1808/4885 |
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | TRIM24 3152/4885TRIM33 3816/4885CA2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.